FDA warns Cookies-n-Milk that mispackaged ready-to-eat cookie dough had undeclared peanut allergen and lacked required hazard controls.
What happened
FDA inspected the McKinney, Texas ready-to-eat cookie dough plant from October 3 to 19, 2023, after a Class 1 recall of Chocolate Chip Edible Cookie Dough cups that contained Peanut Butter Edible Cookie Dough with undeclared peanuts. FDA said the firm's hazard analysis did not treat undeclared allergens from incorrect labeling as a hazard needing a preventive control at packaging/labeling, and did not treat mycotoxins in peanut butter as a hazard needing a supply-chain control. FDA also found Peanut Butter Cup Edible Cookie Dough labels did not declare peanuts and did not list all ingredients, including milk powder, baking soda and salt.
What FDA found
The hazard analysis did not identify undeclared allergens from incorrect labeling as a hazard requiring a preventive control at the packaging/labeling step.
21 CFR 117.130(a)(1)The hazard analysis did not identify mycotoxins, such as aflatoxin, as a hazard requiring a preventive control in peanut butter and peanut butter-containing ingredients.
21 CFR 117.130(a)(1)The firm did not conduct supplier verification for mycotoxins in peanut butter and peanut butter-containing ingredients.
21 CFR 117.405(a)(1); 21 CFR 117.410Peanut Butter Cup Edible Cookie Dough lot 3240 was placed in Chocolate Chip Edible Cookie Dough cups, so the label did not declare peanut, a major food allergen.
section 403(w) of the Act [21 U.S.C. § 343(w)]The Peanut Butter Cup Edible Cookie Dough label did not list all ingredients as common or usual names, including milk powder, baking soda and salt.
section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)]; 21 CFR 101.4The labels also lacked the street address unless it appears in a current directory, and did not include the words “Net Weight.”
21 CFR 101.5(d); 21 CFR 101.7(j)(3)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of steps taken to correct the violations, with an explanation and documentation to prevent recurrence. If corrections cannot be completed in that time, the company must state why and when it will finish.
Who should pay attention
- brands that use preprinted labels for allergen-containing and allergen-free products
- contract manufacturers and co-packers running multiple allergen formulations on shared packaging lines
- food safety and labeling teams at ready-to-eat food companies
This is a summary. Read the original letter on fda.gov.